Effects of substrate deprivation therapy on brain lipids in neonatal GML storage disease mice

Documents similaires

• Substrate deprivation therapy reduces brain ganglioside content and GM1 in neonatal storage disease mice
  par: Kasperzyk, J, et autres
  Publié: (2002)
• Therapeutic assessment of substrate deprivation using NB-DGJ in GM1 storage disease mice
  par: Seyfried, T, et autres
  Publié: (2003)
• Erratum: Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice (Journal of Lipid Research (April 2004) 46 (744-751))
  par: Kasperzyk, J, et autres
  Publié: (2005)
• Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice
  par: Baek, R, et autres
  Publié: (2005)
• N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
  par: Kasperzyk, J, et autres
  Publié: (2004)